{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:04:45Z","timestamp":1793941485524,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UKRI Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008164","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omtn.2024.102237","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:08:00Z","timestamp":1717578480000},"page":"102237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-121X","authenticated-orcid":false,"given":"Sara","family":"Aguti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Ala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-3074","authenticated-orcid":false,"given":"Haiyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102237_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102237_bib2","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/pharmaceutics14112389","article-title":"Antisense oligonucleotide therapy for the nervous system: from bench to bedside with emphasis on pediatric neurology","volume":"14","author":"Amanat","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102237_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen\u00a0\u2013 a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"de Smet","year":"1999","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.omtn.2024.102237_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-200241040-00002","article-title":"Fomivirsen: clinical pharmacology and potential drug interactions","volume":"41","author":"Geary","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omtn.2024.102237_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102237_bib6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2024.102237_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (Inotersen): an antisense oligonucleotide approved for the\u00a0treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtn.2024.102237_bib8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: first global approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102237_bib9","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtn.2024.102237_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102237_bib11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/pharmaceutics14081708","article-title":"Towards personalized allele-specific antisense oligonucleotide therapies for toxic gain-of-function neurodegenerative diseases","volume":"14","author":"Helm","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102237_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102237_bib14","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102237_bib15","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.omtn.2024.102237_bib16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102237_bib17","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"\u00d8stergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102237_bib18","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington\u2019s disease models","author":"Conroy","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2024.102237_bib19","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/brain\/awz139","article-title":"Allele-specific silencing as treatment for gene duplication disorders: Proof-of-principle in autosomal dominant leukodystrophy","volume":"142","author":"Giorgio","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2024.102237_bib20","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In\u00a0vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102237_bib21","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1073\/pnas.1231012100","article-title":"Allele-specific silencing of dominant disease genes","volume":"100","author":"Miller","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102237_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.matbio.2017.12.008","article-title":"Collagen VI disorders: Insights on form and function in the extracellular matrix and beyond","volume":"71\u201372","author":"Lamand\u00e9","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.omtn.2024.102237_bib24","first-page":"3525","article-title":"Collagen VI at a glance","volume":"128","author":"Cescon","year":"2015","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2024.102237_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2044-5040-1-30","article-title":"ColVI myopathies: Where do we stand, where do we go?","volume":"1","author":"Allamand","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2024.102237_bib26","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.bbadis.2014.05.033","article-title":"Defective collagen VI \u03b16 chain expression in the skeletal muscle of patients with collagen VI-related myopathies","volume":"1842","author":"Tagliavini","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2024.102237_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.nmd.2006.07.015","article-title":"A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14\u00a0Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations","volume":"16","author":"Jimenez-Mallebrera","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2024.102237_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtn.2020.05.029","article-title":"Exon-Skipping Oligonucleotides Restore Functional Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD","volume":"21","author":"Aguti","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102237_bib29","doi-asserted-by":"crossref","first-page":"e124403","DOI":"10.1172\/jci.insight.124403","article-title":"A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies","volume":"4","author":"Bolduc","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2024.102237_bib30","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1089\/hum.2012.109","article-title":"Antisense-induced messenger depletion corrects a COL6A2 dominant mutation in Ullrich myopathy","volume":"23","author":"Gualandi","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2024.102237_bib31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.omtn.2017.07.006","article-title":"Gapmer antisense oligonucleotides suppress the mutant allele of COL6A3 and restore functional protein in Ullrich muscular dystrophy","volume":"8","author":"Marrosu","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102237_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-0716-0771-8_16","article-title":"Gapmer antisense oligonucleotides to selectively suppress the mutant allele in COL6A genes in dominant Ullrich congenital muscular dystrophy","volume":"2176","author":"Aguti","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2024.102237_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.74","article-title":"SiRNA-mediated allele-specific silencing of a COL6A3 mutation in a cellular model of dominant Ullrich muscular dystrophy","volume":"3","author":"Bolduc","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102237_bib34","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1038\/mtna.2014.22","article-title":"Allele-specific gene silencing of mutant mRNA restores cellular function in Ullrich congenital muscular dystrophy fibroblast","volume":"3","author":"Naguchi","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102237_bib35","first-page":"14514","volume":"266","author":"Monia","year":"1993"},{"key":"10.1016\/j.omtn.2024.102237_bib36","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2024.102237_bib37","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: An emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omtn.2024.102237_bib38","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","article-title":"LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts","volume":"7","author":"Touznik","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2024.102237_bib39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2018.11.007","article-title":"Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics","volume":"14","author":"Le","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102237_bib40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/ijms20051088","article-title":"Gymnotic delivery of LNA mixmers targeting viral SREs induces HIV-1 mRNA degradation","volume":"20","author":"Hillebrand","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2024.102237_bib41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtn.2024.102237_bib42","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/mt.2008.205","article-title":"Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms","volume":"17","author":"Aartsma-Rus","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102237_bib43","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/nar\/28.6.1340","article-title":"Effects of RNA secondary structure on cellular antisense activity","volume":"28","author":"Vickers","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102237_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/cb200253h","article-title":"Small molecule inhibition of RISC loading","volume":"7","author":"Tan","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.omtn.2024.102237_bib45","first-page":"1032","article-title":"Analysis of sequencing data for probing RNA secondary structures and protein-RNA binding in studying posttranscriptional regulations","volume":"17","author":"Hu","year":"2016","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.omtn.2024.102237_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002248","article-title":"Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi","volume":"3","author":"Ohnishi","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102237_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102178","article-title":"Optimized allele-specific silencing of the dominant-negative COL6A1 G293R substitution causing collagen VI-related dystrophy","volume":"35","author":"Brull","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102237_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12844-z","article-title":"Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes","volume":"7","author":"Magner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2024.102237_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic","volume":"226","author":"Watts","year":"2014","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.omtn.2024.102237_bib50","doi-asserted-by":"crossref","first-page":"9350","DOI":"10.1093\/nar\/gkv964","article-title":"A cytoplasmic pathway for gapmer antisense oligonucleotide mediated gene silencing in mammalian cells","volume":"43","author":"Castanotto","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102237_bib51","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102237_bib52","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtn.2024.102237_bib53","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.3390\/ijms23084410","article-title":"CRISPR\/Cas9-mediated allele-specific disruption of a dominant COL6A1 pathogenic variant improves collagen VI network in patient fibroblasts","volume":"23","author":"L\u00f3pez-M\u00e1rquez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2024.102237_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejpn.2017.07.009","article-title":"Somatic mosaicism represents an underestimated event underlying collagen 6-related disorders","volume":"21","author":"D'Amico","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.omtn.2024.102237_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/humu.22691","article-title":"Mosaicism for dominant collagen 6 mutations as a cause for intrafamilial phenotypic variability","volume":"36","author":"Donkervoort","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2024.102237_bib56","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:04:51Z","timestamp":1728025491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253124001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2162253124001240"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102237","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102237"}}